SEC Form 4 · accession 0000905148-16-001655

REATA PHARMACEUTICALS INC · RETA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).

Reporting owner

CPMG Inc

Director · 10% Owner

Period of report

Jun 1, 2016

Accepted (ET)

Jun 3, 2016 · 3:58 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001358762

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Class A common stock^F1,F2	Jun 1, 2016	P	150	$13.4199	A	150	I	By Blackwell Partners, LLC
Class A common stock^F1,F2	Jun 1, 2016	P	380	$13.4199	A	380	I	By Crested Crane, LP
Class A common stock^F1,F2	Jun 1, 2016	P	440	$13.4199	A	440	I	By Flamingo Fund, LP
Class A common stock^F1,F2	Jun 1, 2016	P	1,600	$13.4199	A	1,600	I	By Gallopavo, LP
Class A common stock^F1,F2	Jun 1, 2016	P	1,680	$13.4199	A	1,680	I	By Roadrunner Fund, LP
Class A common stock^F1,F2	Jun 1, 2016	P	2,330	$13.4199	A	2,330	I	By Sandpiper Fund, LP
Class A common stock^F1,F2	Jun 1, 2016	P	830	$13.4199	A	14,323	I	By Mallard Fund, LP
Class A common stock^F1,F2	Jun 1, 2016	P	625	$13.4199	A	57,974	I	By Yellow Warbler, LP
Class A common stock^F2	holding	—	—		—	27,651	I	By Kestrel Fund, LP
Class A common stock^F2	holding	—	—		—	252,706	I	By Willet Fund, LP
Class A common stock^F2	holding	—	—		—	11,076	I	By CD Fund, LP
Class A common stock^F2	holding	—	—		—	134	I	By Redbird Life Sciences Partners, LP
Class A common stock	holding	—	—		—	113	D

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

F1This price reflects the weighted average purchase price for open-market purchases on June 1, 2016, within a $1.00 range. The actual prices for these transactions range from $13.32 to $13.50, inclusive. The Reporting Person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
F2The Reporting Person is the investment manager of each of: Blackwell Partners, LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Remarks

Mr. McGaughy, Jr., a co-director and co-shareholder of the Reporting Person, serves on the Issuer's Board of Directors (the "Board") as a representative of the Reporting Person. By virtue of his representation on the Board, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the Reporting Person is deemed to be a director by deputization.